DKK1 and neoplasm: To further enhance efficacy for the inhibition of tumor growth, a combination treatment of an anti-DKK1 antibody with an anti-PD1 antibody has yielded promising clinical efficacy in clinical trials of cancer therapy [28, 42–44].